151 related articles for article (PubMed ID: 36420802)
21. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
[TBL] [Abstract][Full Text] [Related]
22. A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders.
Yoshida K; Sanada M; Kato M; Kawahata R; Matsubara A; Takita J; Shih LY; Mori H; Koeffler HP; Ogawa S
Leukemia; 2011 Jan; 25(1):184-6. PubMed ID: 20962861
[No Abstract] [Full Text] [Related]
23. Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
[TBL] [Abstract][Full Text] [Related]
24. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression.
DiNardo CD; Jabbour E; Ravandi F; Takahashi K; Daver N; Routbort M; Patel KP; Brandt M; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2016 Apr; 30(4):980-4. PubMed ID: 26228814
[No Abstract] [Full Text] [Related]
25. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.
Kosmider O; Gelsi-Boyer V; Slama L; Dreyfus F; Beyne-Rauzy O; Quesnel B; Hunault-Berger M; Slama B; Vey N; Lacombe C; Solary E; Birnbaum D; Bernard OA; Fontenay M
Leukemia; 2010 May; 24(5):1094-6. PubMed ID: 20376084
[No Abstract] [Full Text] [Related]
26. IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7)(q10;p10).
Westman MK; Pedersen-Bjergaard J; Andersen MT; Andersen MK
Leukemia; 2013 Apr; 27(4):957-9. PubMed ID: 23192014
[No Abstract] [Full Text] [Related]
27. Clone wars: co-occurrence of IDH2 R140Q and R172K in myelodysplastic syndromes.
Rosso V; Petiti J; Dragani M; Andreani G; Croce E; Lo Iacono M; Saglio G; Fava C; Cilloni D
Ann Hematol; 2020 Apr; 99(4):891-893. PubMed ID: 32016578
[No Abstract] [Full Text] [Related]
28. Myelodysplastic Syndrome and Sweet's Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1.
Snyder R; Libby T; Raciti P; Amin B; Jacobson M; Rakheja D; Fleming K; Bartenstein M; Zhu C; Goel S; Verma AK; Shastri A
Anticancer Res; 2018 Apr; 38(4):2201-2205. PubMed ID: 29599340
[TBL] [Abstract][Full Text] [Related]
29. A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations.
Chou WC; Huang YN; Huang CF; Tseng MH; Tien HF
Blood; 2010 Jul; 116(3):495-6. PubMed ID: 20651083
[No Abstract] [Full Text] [Related]
30. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM; Baer MR; Yang J; Prebet T; Lee S; Schiller GJ; Dinner SN; Pigneux A; Montesinos P; Wang ES; Seiter KP; Wei AH; De Botton S; Arnan M; Donnellan W; Schwarer AP; Récher C; Jonas BA; Ferrell PB; Marzac C; Kelly P; Sweeney J; Forsyth S; Guichard SM; Brevard J; Henrick P; Mohamed H; Cortes JE
Lancet Haematol; 2023 Jan; 10(1):e46-e58. PubMed ID: 36370742
[TBL] [Abstract][Full Text] [Related]
31. Prognostic mutations in persons with isolated neutropenia myelodysplastic syndrome.
Shi Z; Qin T; Xu Z; Li B; Huang H; Zhang H; Fang L; Pan L; Hu N; Qu S; Huang G; Gale RP; Xiao Z
Leuk Lymphoma; 2019 Nov; 60(11):2835-2837. PubMed ID: 31056995
[No Abstract] [Full Text] [Related]
32. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
[TBL] [Abstract][Full Text] [Related]
33. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.
Patnaik MM; Hanson CA; Hodnefield JM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
Leukemia; 2012 Jan; 26(1):101-5. PubMed ID: 22033490
[TBL] [Abstract][Full Text] [Related]
34. Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.
Tischer A; Antelo G; Coltro G; Finke CM; Gonsalves W; Pardanani A; Ketterling R; Mangaonkar A; Gangat N; Tefferi A; Patnaik MM; Lasho TL
Leuk Res; 2019 Dec; 87():106264. PubMed ID: 31706195
[No Abstract] [Full Text] [Related]
35. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
36. Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes.
Ganguly BB
Curr Cancer Drug Targets; 2017; 17(7):586-602. PubMed ID: 28359242
[TBL] [Abstract][Full Text] [Related]
37. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
Ann Hematol; 2012 Apr; 91(4):519-25. PubMed ID: 21997850
[TBL] [Abstract][Full Text] [Related]
38. Single nucleotide polymorphisms in the human TNF gene are associated with anaemia and neutropenia in a cohort of patients with de novo myelodysplastic syndrome.
Parnes A; Nikiforow S; Berliner N; Vanasse GJ
Br J Haematol; 2010 Sep; 150(6):700-1. PubMed ID: 20618340
[No Abstract] [Full Text] [Related]
39. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.
Chen J; Yang J; Cao P
Mini Rev Med Chem; 2016; 16(16):1344-1358. PubMed ID: 27292784
[TBL] [Abstract][Full Text] [Related]
40. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
